STAAR Surgical Reports Second Quarter 2016 Results MONROVIA, CA

Surgical Reports Second Quarter 2016 Results

MONROVIA, CA, August 3, 2016---STAAR Surgical Company

(NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye

today reported financial results for the second quarter ended July 1, 2016.

Second Quarter 2016 Overview

"We delivered record quarterly

net sales of $21 million and achieved record quarterly ICL sales and units as well. Continuing strength and momentum is

evident in most of the Asia Pacific region leading with China and in Europe leading with Germany," said Caren Mason, President

and CEO. "We advanced a number of strategic priorities for 2016 in the quarter including the finalization of four additional

Strategic Cooperation Agreements in the Asia Pacific region. During the quarter, we also finalized the clinical study agreements

for our first-in-man implants of the Presbyopic ICL and we are on schedule to provide lenses for surgeries scheduled during the

third quarter. In addition, we continued the evaluation process concerning our Cataract Care strategy and have decided to discontinue

the manufacturing of silicone IOL lenses for distribution in North America. Consequently, our proprietary Collamer

material IOL lenses will be the only lens version offered in North America at this time. We are currently developing a competitive

commercial strategy to encourage users of silicone IOL lenses to use our nanoFLEX Collamer lenses," added Ms.

Net sales were $21.0 million for the second quarter of 2016,

up 12% compared to $18.7 million reported in the prior year quarter. On a constant currency basis, second quarter net sales increased

10% compared to the prior year quarter. The sales increase was driven by ICL revenue and unit growth of 26% and 18%, respectively,

with strong double-digit unit growth in all of the Asia Pacific ("APAC") markets and in Germany. These increases were

partially offset by lower IOL revenues and lower sales of injector parts. For the first half of 2016, ICL revenue and unit growth

was 17% and 9%, respectively.

For the second quarter of 2016, gross profit margin was 69.7%

compared to the prior year period of 66.3%. An increased mix of higher margin ICL units, higher average selling prices, and lower

ICL unit costs improved gross margin by approximately 7.0 points which was partially offset by approximately 3.6 points in higher

IOL unit costs and reserves for the discontinuation of the Company's silicone IOL product line.

Operating expenses for the quarter increased $2.7 million to

$16.8 million primarily due to costs related to quality system improvements and investments made in the international selling and

marketing organizations. General and administrative expense was $4.9 million and the change from the prior year quarter was not

material. Marketing and selling expense was $7.2 million, $1.3 million higher than the prior year quarter due to higher international

selling and marketing expenses, including the cost of direct selling in Germany. Research and development expense was $4.7 million,

an increase of $1.1 million due to investments in quality system improvements, regulatory and clinical affairs, and project-related

spending, partially offset by lower remediation expenses. Remediation expense for the quarter was on budget.

The net loss for the second quarter of 2016 was $2.1 million

or $0.05 per share compared with a net loss of $1.6 million or $0.04 per share for the prior year quarter. Charges of $0.4 million

or $0.01 per share associated with the discontinuation of the silicone IOL product line are included in the second quarter results.

The adjusted net loss for the second quarter of 2016 was $0.9

million or $0.02 per share, compared with adjusted net income of $0.2 million or breakeven per share for the prior year quarter.

The reconciliation between GAAP and non-GAAP financial information is provided in the financial tables included with this release.

Cash and cash equivalents at July 1, 2016 totaled $12.7 million,

compared to $15.3 million at the end of the second quarter of 2015 and $9.0 million at the end of the first quarter 2016. Continued

focus on optimizing the Company's cash position through revenue growth, expense mitigation, working capital management, and

equipment leasing generated the increase in cash from the first quarter of 2016 to the second quarter of 2016. The Company has

used $0.5 million in cash from operating activities during the first six months of the year.

The Company will host a conference call and webcast on Wednesday,

August 3 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operational progress. To access the conference

call (Conference ID 48714531), please dial 855-765-5684 for domestic participants and 262-912-6252 for international participants.

The live webcast can be accessed from the investor relations section of the STAAR website at www.staar.com.

A taped replay of the conference call (Conference ID 48714531)

will be available beginning approximately one hour after the call's conclusion for seven days. This replay can be accessed

by dialing 855-859-2056 for domestic callers and 404-537-3406 for international callers. An archived webcast will also be available

Use of Non-GAAP Financial Measures

This press release includes supplemental non-GAAP financial

information, which STAAR believes investors will find helpful in understanding its operating performance.

The Company conducts a significant part of its activities outside

the U.S. It receives sales revenue and pays expenses principally in U.S. dollars, Swiss francs, Japanese yen and euros. The exchange

rates between dollars and non-U.S. currencies can fluctuate greatly and can have a significant effect on the Company's results

when reported in U.S. dollars. When preparing its financial statements in conformity with GAAP, the Company translates foreign

currency sales and expenses denominated in Japanese yen to dollars at the weighted average of exchange rates in effect during the

period. As a result, the Company's reported performance may be significantly affected by currency fluctuations. In order to compare

the Company's performance from period to period without the effect of currency, the Company will apply the same average exchange

rate applicable in the prior period, or the "constant currency" rate to sales or expenses in the current period as well.

Because changes in currency are outside of the control of the Company and its managers, management finds this non-GAAP measure

useful in determining the long-term progress of its initiatives and determining whether its managers are achieving their performance

goals. The Company believes that the non-GAAP constant-currency sales results measures provided in this press release are similarly

useful to investors to give insight on long term trends in the Company's performance without the external effect of changes in

relative currency values. The table below shows sales results calculated in accordance with GAAP, the effect of currency, and the

resulting non-GAAP measure expressed in constant currency.

"Adjusted Net Income (or Loss)" excludes the following

items that are included in "Net Income (or Loss)" as calculated in accordance with U.S. generally accepted accounting

principles ("GAAP"): gain or loss on foreign currency transactions, stock-based compensation expenses, and quality

remediation expenses.

Management believes that "Adjusted Net Income (or Loss)"

is useful to investors in gauging the outcome of the key drivers of the business performance: the ability to increase sales revenue

and our ability to increase profit margin by improving the mix of high value products while reducing the costs over which management

Management has excluded quality remediation expenses because

their inclusion may mask underlying trends in our business performance.

Management has also excluded gains and losses on foreign currency

transactions because of the significant fluctuations that can result from period to period as a result of market driven factors.

Stock-based compensation expenses consist of expenses for stock

options and restricted stock under the Financial Accounting Standards Board's Accounting Standards Codification (ASC) 718.

In calculating Adjusted Net Income (or Loss) STAAR excludes these expenses because they are non-cash expenses and because of the

complexity and considerable judgment involved in calculating their values. In addition, these expenses tend to be driven by fluctuations

in the price of our stock and not by the same factors that generally affect our other business expenses.

About STAAR Surgical

STAAR, which has been dedicated solely to ophthalmic surgery

for over 30 years, designs, develops, manufactures and markets implantable lenses for the eye with companion delivery systems.

These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses.

All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR's lens used in

refractive surgery is called an Implantable Collamer Lens or "ICL". Over 600,000 Visian ICLs have been implanted

to date. To learn more about the ICL go to: www.visianinfo.com. STAAR has approximately 360 employees and markets lenses in over

60 countries. Headquartered in Monrovia, CA, the company operates manufacturing facilities in Aliso Viejo, CA and Monrovia, CA.

For more information, please visit the Company's website at www.staar.com.

All statements in this press release that are not statements

of historical fact are forward-looking statements, including statements about any of the following: any financial projections,

including those relating to working capital requirements; the plans, strategies, and objectives of management for future operations

or prospects for achieving such plans, expectations for sales, marketing and clinical initiatives, investment imperatives, and

any statements of assumptions underlying any of the foregoing. Important additional factors that could cause actual results to

differ materially from those indicated by such forward-looking statements are set forth in the Company's Annual Report on

Form 10-K for the year ended January 1, 2016 under the caption "Risk Factors," which is on file with the Securities

and Exchange Commission and available in the "Investor Information" section of the company's website under the